These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 16033704)

  • 21. Current management of the cognitive dysfunction in Parkinson's disease: how far have we come?
    Vale S
    Exp Biol Med (Maywood); 2008 Aug; 233(8):941-51. PubMed ID: 18535172
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pramipexole in the treatment of Parkinson's disease: new developments.
    Möller JC; Oertel WH
    Expert Rev Neurother; 2005 Sep; 5(5):581-6. PubMed ID: 16162081
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Dopamine dysregulation syndrome, addiction and behavioral changes in Parkinson's disease.
    Merims D; Giladi N
    Parkinsonism Relat Disord; 2008; 14(4):273-80. PubMed ID: 17988927
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Impact of Parkinson's disease and dopaminergic medication on proprioceptive processing.
    Mongeon D; Blanchet P; Messier J
    Neuroscience; 2009 Jan; 158(2):426-40. PubMed ID: 18996173
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Drug insight: Continuous dopaminergic stimulation in the treatment of Parkinson's disease.
    Olanow CW; Obeso JA; Stocchi F
    Nat Clin Pract Neurol; 2006 Jul; 2(7):382-92. PubMed ID: 16932589
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Dopamine and cognitive functioning in de novo subjects with Parkinson's disease: effects of pramipexole and pergolide on working memory.
    Costa A; Peppe A; Dell'Agnello G; Caltagirone C; Carlesimo GA
    Neuropsychologia; 2009 Apr; 47(5):1374-81. PubMed ID: 19428401
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Dopaminergic influence on disturbed spatial discrimination in Parkinson's disease.
    Shin HW; Kang SY; Sohn YH
    Mov Disord; 2005 Dec; 20(12):1640-3. PubMed ID: 16092109
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A case of hedonistic homeostatic dysregulation.
    Kessel BL
    Age Ageing; 2006 Sep; 35(5):540-1. PubMed ID: 16799178
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The thrill of reckless driving in patients with Parkinson's disease: an additional behavioural phenomenon in dopamine dysregulation syndrome?
    Avanzi M; Baratti M; Cabrini S; Uber E; Brighetti G; Bonfà F
    Parkinsonism Relat Disord; 2008; 14(3):257-8. PubMed ID: 17561433
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Rasagiline improves quality of life in patients with early Parkinson's disease.
    Biglan KM; Schwid S; Eberly S; Blindauer K; Fahn S; Goren T; Kieburtz K; Oakes D; Plumb S; Siderowf A; Stern M; Shoulson I;
    Mov Disord; 2006 May; 21(5):616-23. PubMed ID: 16450340
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The dopaminergic nigrostriatal system and Parkinson's disease: molecular events in development, disease, and cell death, and new therapeutic strategies.
    Hodaie M; Neimat JS; Lozano AM
    Neurosurgery; 2007 Jan; 60(1):17-28; discussion 28-30. PubMed ID: 17228250
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Continuous dopaminergic stimulation by Duodopa in advanced Parkinson's disease: Efficacy and safety].
    Annic A; Devos D; Seguy D; Dujardin K; Destée A; Defebvre L
    Rev Neurol (Paris); 2009; 165(8-9):718-27. PubMed ID: 19150100
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The hypothesis of the genesis of motor complications and continuous dopaminergic stimulation in the treatment of Parkinson's disease.
    Stocchi F
    Parkinsonism Relat Disord; 2009 Jan; 15 Suppl 1():S9-S15. PubMed ID: 19131046
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Hypersexuality and paraphilia induced by selegiline in Parkinson's disease: report of 2 cases.
    Shapiro MA; Chang YL; Munson SK; Okun MS; Fernandez HH
    Parkinsonism Relat Disord; 2006 Sep; 12(6):392-5. PubMed ID: 16730214
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Dopaminergic modulation of cognitive interference after pharmacological washout in Parkinson's disease.
    Fera F; Nicoletti G; Cerasa A; Romeo N; Gallo O; Gioia MC; Arabia G; Pugliese P; Zappia M; Quattrone A
    Brain Res Bull; 2007 Sep; 74(1-3):75-83. PubMed ID: 17683792
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Rasagiline-associated motor improvement in PD occurs without worsening of cognitive and behavioral symptoms.
    Elmer L; Schwid S; Eberly S; Goetz C; Fahn S; Kieburtz K; Oakes D; Blindauer K; Salzman P; Oren S; Prisco UL; Stern M; Shoulson I; ;
    J Neurol Sci; 2006 Oct; 248(1-2):78-83. PubMed ID: 16828804
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Recent advances in Parkinson's disease therapy: use of monoamine oxidase inhibitors.
    Henchcliffe C; Schumacher HC; Burgut FT
    Expert Rev Neurother; 2005 Nov; 5(6):811-21. PubMed ID: 16274338
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Dopamine agonists for Parkinson's disease.
    Drug Ther Bull; 1991 Jan; 29(2):7-8. PubMed ID: 1682118
    [No Abstract]   [Full Text] [Related]  

  • 39. Long-term effect of initiating pramipexole vs levodopa in early Parkinson disease.
    Parkinson Study Group CALM Cohort Investigators
    Arch Neurol; 2009 May; 66(5):563-70. PubMed ID: 19433655
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Is dopamine agonist therapy associated with developing pathological gambling in Parkinson's disease patients?
    Zand R
    Eur Neurol; 2008; 59(3-4):183-6. PubMed ID: 18230877
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.